Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of N-Methylpiperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methylpiperidine SCHEMBL1050930 | 0.97 | CYP1A2 (0.46) | CYP1A2TDP1LMNAFFAR3LCK | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL1687141 | 0.97 | CYP1A2 (0.50) | CYP1A2TDP1LMNAFFAR3LCK | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL5425502 | 0.94 | CYP1A2 (0.48) | CYP1A2TDP1LMNAFFAR3LCK | |
| N-Methylpiperidine SCHEMBL11210549 | 0.91 | CYP1A2 (0.50) | CYP1A2TDP1LMNAMAPK1SMN1; SMN2 | |
| N-Methylpiperidine SCHEMBL3849400 | 0.88 | ALDH1A1 (0.47) | CYP1A2TDP1LMNAMAPK1SMN1; SMN2 | |
| N-Methylpiperidine SCHEMBL27874745 | 0.86 | CYP1A2 (0.46) | CYP1A2TDP1LMNAALDH1A1HTT | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL9368873 | 0.85 | KDM4E (0.44) | CYP1A2TDP1LMNAMAPK1SMN1; SMN2 | |
| N-Methylpiperidine SCHEMBL29238591 | 0.85 | CYP1A2 (0.41) | CYP1A2TDP1LMNAMAPK1SMN1; SMN2 | |
| N-Methylpiperidine SCHEMBL3416209 | 0.83 | FFAR3 (0.53) | CYP1A2TDP1LMNAFFAR3MAPK1 | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL3408004 | 0.83 | FFAR3 (0.53) | CYP1A2TDP1LMNAFFAR3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533595-A | Method for treating substance abuse | 感知神经科学公司 | 2021-03-19 | — | — | CN | claimed |
| CN-110143904-A | A kind of preparation method of semi-synthetic astaxanthin intermediate zeaxanthin | 班磊 | 2019-08-20 | — | — | CN | claimed |
| CN-108586306-A | A method of lutein and zeaxanthin are detached using ionic liquid strengthening extraction | 华东理工大学 | 2018-09-28 | — | — | CN | claimed |
| EP-2265617-B1 | SOLVENTS | BIONIQS LTD (GB) | 2014-07-02 | — | — | EP | claimed |
| EP-2265617-A1 | SOLVENTS | Bioniqs Limited (GB) | 2010-12-29 | — | — | EP | claimed |
| WO-2009034329-A1 | SOLVENTS | BIONIQS LIMITED (GB) | 2009-03-19 | — | — | WO | claimed |
| US-6361940-B1 | IMMOBILIZATION; GENETIC ENGINEERING | QIAGEN GENOMICS, INC. | 2002-03-26 | — | — | US | claimed |
| CN-119731370-A | Method and system for coating a drug container, cleaning a drug container and checking a drug container for particles and defects | 二氧化硅医疗产品公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119546605-A | Protein degradation agent | 苏州开拓药业股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250066860-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2025-02-27 | — | — | US | disclosed |
| US-12195803-B2 | Methods and materials for assessing and treating cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024027694-A9 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20240393290-A1 | ELECTROCHEMICAL GAS SENSOR AND ELECTROLYTE FOR AN ELECTROCHEMICAL GAS SENSOR | Dräger Safety AG & Co. KGaA (DE) | 2024-11-28 | — | — | US | disclosed |
| US-4234578-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1980-11-18 | — | — | US | disclosed |
| US-4147864-A | Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4110533-A | PROCESS FOR THE MANUFACTURE OF ENOL DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4073902-A | ANTIMICROBIAL COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
| US-4069324-A | CEPHALOSPORIN ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3932465-A | ANTIBIOTIC | CIBA-GEIGY CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |